Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Patient enrollment in Phase III trial of laquinimod completed
Laquinimod sodium (ABR-215062 sodium) | Immunomodulator | MedChemExpress
Letter to investigators involved in the Arpeggio study of Laquinimod …
Teva drops development of laquinimod - PharmaTimes
Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF
Teva launches personalised digital support for MS patients - PMLiVE
Active Biotech regains rights of laquinimod from Teva
Laquinimod, an Oral Product in Development for the Treatment of Relapsing Remitting Multiple Sclerosis Steve Glenski, PharmD Medical Affairs Teva Neuroscience. - ppt download
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Linomide - Wikipedia
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis - Giancarlo Comi, Yuval Dadon, Nissim Sasson, Joshua R Steinerman, Volker Knappertz, Timothy L Vollmer, Alexey Boyko, Patrick Vermersch, Tjalf
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor | PNAS
Meet the Compound: Laquinimod – HD Insights
CONFIDENTIAL DRAFT: Failure Scenario (PEP Not Achieved)
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells - Dobson - 2016 - Journal of Neurochemistry - Wiley Online Library
After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Teva & Active Biotech Press Release: November 4, 2014
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity | PLOS ONE
Teva Relinquishes Laquinimod, Returning the Rights to Active Biotech - Pharmaceutical Processing World
